NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

Goldman Sachs Upgrades Chime to Buy with Strong Upside Potential

Goldman Sachs upgrades Chime to Buy with a $27 price target, citing strong take-rate potential from the new Chime Card and revenue diversification strategy.

Goldman Sachs Upgrades Chime to Buy with Strong Upside Potential
Credit: Chime/Nasdaq
Already have an account? Sign in.
12/01/2025 · 10:04 AM
CHYM
/ Read more

Feed↓

Kyntra Bio Scores First Analyst Coverage: Oppenheimer Initiates Outperform with $35 Target
07/06/2026 · 5:44 PM

Kyntra Bio Scores First Analyst Coverage: Oppenheimer Initiates Outperform with $35 Target

Kyntra Bio gains analyst support as its cancer drugs advance, with key Phase 2 data expected to drive future growth.

/ Subscriber only
Aligos Therapeutics Shares Soar on Major China Licensing Agreement and Regulatory Milestone for Chronic Hepatitis B Treatment
07/06/2026 · 5:15 PM

Aligos Therapeutics Shares Soar on Major China Licensing Agreement and Regulatory Milestone for Chronic Hepatitis B Treatment

Aligos Therapeutics announces $25 million upfront payment and Breakthrough Therapy Designation in China for pevifoscorvir sodium.

/ Subscriber only
Vertex to Acquire Crinetics for $10 Billion in Major Rare Disease Expansion
Featured/ 07/06/2026 · 4:38 PM

Vertex to Acquire Crinetics for $10 Billion in Major Rare Disease Expansion

The deal adds PALSONIFY (paltusotine) and late-stage CAH therapy to Vertex’s portfolio.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe